Ratings by B.Riley (Madison El-Saadi)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/5/2026 | Spruce Biosciences, Inc. | SPRB | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2026 | Anika Therapeutics | ANIK | New Coverage | Buy (N/A) |
21.03 (20.60) |
-2.04% | Details | |
| 9/15/2026 | iBio, Inc. | IBIO | New Coverage | Buy (N/A) |
1.20 (0.84) |
-30% | Details | |
| 9/14/2026 | Capricor Therapeutics | CAPR | Upgrade | Buy (Neutral) |
8.30 (5.88) |
-29.16% | Details | |
| 9/11/2026 | Neuronetics | STIM | New Coverage | Buy (N/A) |
3.04 (2.01) |
-33.88% | Details | |
| 8/14/2026 | Eton Pharmaceuticals | ETON | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2026 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Buy (N/A) |
|
Details | ||
| 8/10/2026 | Vanda Pharmaceuticals | VNDA | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2026 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2026 | Capricor Therapeutics | CAPR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/27/2026 | Capricor Therapeutics | CAPR | Downgrade | Neutral (Buy) |
19.70 (5.88) |
-70.15% | Details | |
| 7/21/2026 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2026 | Spruce Biosciences, Inc. | SPRB | New Coverage | Buy (N/A) |
51.74 (42.73) |
-17.41% | Details | |
| 5/13/2026 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2026 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2026 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 4/24/2026 | Compass Pathways | CMPS | New Coverage | Buy (N/A) |
8.75 (11.84) |
35.31% | Details | |
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2026 | Eton Pharmaceuticals | ETON | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2026 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2026 | Vanda Pharmaceuticals | VNDA | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2026 | Fennec Pharmaceuticals Inc. | FENC | New Coverage | Buy (N/A) |
7.79 (10.38) |
33.25% | Details | |
| 1/2/2026 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/31/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Capricor Therapeutics | CAPR | Maintain | Buy (Buy) |
|
Details | ||
| 11/5/2025 | Vanda Pharmaceuticals | VNDA | New Coverage | Buy (N/A) |
4.47 (4.01) |
-10.29% | Details | |
| 10/9/2025 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2025 | Axsome Therapeutics | AXSM | New Coverage | Buy (N/A) |
117.62 (156.31) |
32.89% | Details | |
| 8/8/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
0.51 (2.47) |
384.31% | Details | |
| 6/26/2025 | Capricor Therapeutics | CAPR | New Coverage | Buy (N/A) |
9.25 (5.88) |
-36.43% | Details | |
| 5/16/2025 | Eton Pharmaceuticals | ETON | Maintain | Neutral (N/A) |
|
Details | ||
| 3/19/2025 | Eton Pharmaceuticals | ETON | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2025 | Eton Pharmaceuticals | ETON | New Coverage | Buy (N/A) |
11.99 (49.30) |
311.18% | Details | |
| 11/4/2024 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2024 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2024 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details |
